Related Experiment Video
Updated: Jan 10, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
The Incidence, Severity and Risk Factors of Renal Injury in Lung Cancer Patients Receiving Osimertinib Therapy: A
Jieshan Lin1,2, Xiaoying Dong1,3, Wenfang Tang4,5
1Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.
Aim:
The high burden of lung cancer in developing countries has led to the widespread use of EGFR inhibitors like osimertinib. However, little is known about the prevalence and risk factors of renal injury associated with osimertinib use. Therefore, this study aims to investigate the incidence, severity and risk factors of renal injury in patients receiving osimertinib in the real world.
Methods:
We retrospectively analyzed 1138 patients with lung cancer treated with osimertinib. Renal injury was defined as an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2 and/or the presence of proteinuria. Multivariable logistic regression models were used to identify independent risk factors for renal injury.
Results:
Totally, 215 (18.89%) patients developed renal injury during follow-up. Most cases of renal injury were transient (149/1138, 13.09%), while sustained renal injury accounted for 5.8% (66/1138) of the total cohort. Impaired renal function (eGFR < 60 mL/min/1.73m2) was observed in 136 (11.95%) patients, predominantly at a moderate stage (eGFR 30-59), and proteinuria was present in 100 (8.79%) patients, primarily of mild severity. Among patients with renal injury, 73.53% had a mild creatinine elevation (< 50% increase from baseline). Moreover, the mean time to renal injury onset was 7.92 months (SD 8.34), with a mean recovery time of 4.21 months (SD 6.31). Importantly, age ≥ 60 years (OR = 2.307, 95% CI: 1.348-3.947, p = 0.002) and baseline renal injury (OR = 20.942, 95% CI: 8.398-52.223, p < 0.001) were significant independent risk factors for sustained renal injury.
Conclusions:
This study demonstrates that renal injury is not rare in lung cancer patients treated with osimertinib, particularly in patients aged ≥ 60 years or with pre-existing renal injury. Although most cases are reversible, regular monitoring of renal function is strongly recommended for these patients.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:22Acute Kidney Injury I: Introduction
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:22Acute Kidney Injury VI: Nursing Management
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...